- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 11
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of September 11.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 11.
Number 5: Poster presentations at last week’s European Society for Medical Oncology conference included the results of 5 studies on biosimilar trastuzumab candidates.
Number 4: Sandoz announced that the FDA has accepted its Biologics License Application for a proposed rituximab biosimilar.
Number 3: During a panel at the 2017 AAM Biosimilars Council Conference, regulatory leaders from Pfizer and Sandoz shared their experiences with the development of their biosimilar products.
Number 2: Dr Kashyap Patel, managing partner at Carolina Blood and Cancer Care, addresses challenges surrounding biosimilars in the US marketplace.
Number 1: This week, the FDA approved ABP 215, the first bevacizumab biosimilar.
Finally, last week, our newsletter asked you how important it is to educate patients about biosimilar treatments. To view results of the poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
